Navigation Links
Lotus Pharmaceuticals, Inc. Again Awarded GSP Certification

BEIJING, June 29 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today reported it received a Good Supply Practices ("GSP") certificate from the Chinese State Food & Drug Administration ("SFDA") for the second time since 2003.

Liang Fang Pharmaceutical, Ltd., operated by Lotus, passed the SFDA's GSP field inspection and documentation requirement for, among other items, its sales management system, storage and transportation system, qualifications of medical and management personnel, drugs quality control system, drugs labeling and packaging. To maintain drugs safety, post sale services and systematic quality control of drugs out of production into the circulation, the SFDA requires licensed drug distributors to follow the international principles and guidelines of GSP. The SFDA focuses on quality assurance systems, tracking systems, storage and transportation systems and handling procedures and inspects drugs distributors every five years.

"We are delighted to be awarded with GSP certification because it represents the highest honor that a licensed pharmaceutical sales enterprise is eligible to receive in China for its compliance with the government's high quality standards and efficient management system control," commented Dr. Zhongyi Liu, Chairman and CEO of Lotus. "We are committed to providing safe drugs and in addition to our current state-of-art warehouse, we are planning on the construction of a high standard modern storage facility of 10000 sqm in Inner Mongolia in order to meet the increasing demand for our drugs."

About Lotus Pharmaceuticals, Inc. ( )

Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. More than 8,000 products are sold by Liang Fang directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intent," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may," or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the SFDA and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K and its older filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

    Lotus Pharmaceuticals, Inc.
     Yan Zeng, CFO

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Lotus Pharmaceuticals, Inc. to Exhibit at the 2009 International Conference for Bioeconomy
2. Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
3. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
4. iEnterprises Launches iComply, Lotus Notes Email Archiving and Compliance Software
5. Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug
6. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
7. Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
8. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
9. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
10. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
11. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
Breaking Medicine Technology: